Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

Cannon, Christopher P., Steinberg, Benjamin A., Murphy, Sabina A., Mega, Jessica L., Braunwald, Eugene·2006·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2006.04.070

Cited by (772)

Items 701–772 of 772

  1. Identifying and characterizing caveolin-1 derived peptides : a novel approach to promoting nitric oxide release from the endothelium
    Andy Trane · 2016 · cIRcle (University of British Columbia)
  2. Risikofaktorenmanagement bei koronarer Herzerkrankung
    Ephraim B. Winzer, Gerhard C Schuler · 2014 · Herz
  3. The effect of statins on carotid intima-media thickness in patients with acute coronary syndrome
    Bijan Zamani, Afshan Sharghi, Zahra Hoseini · 2017 · International Journal of Scientific Reports
  4. Is it any real cause of safety concern regarding high-dose statin treatment?
    Otto Mayer · 2017 · Medicína pro praxi
  5. Drugs that affect lipid metabolism
    Ivar Aursnes · 2009 · Side effects of drugs annual
  6. Propuesta personal de actualización para el tratamiento de la hipercolesterolemia en Colombia
    Alonso Merchan-V · 2017 · Revista Colombiana de Cardiología
  7. Protection of Microcirculation during PCI
    Arindam Pande, Rabin Chakraborty · 2017 · Jaypee Brothers Medical Publishers (P) Ltd. eBooks
  8. Stratifikasi Risiko, Cost-Analysis dan Jaminan Kesehatan Nasional di Bidang Kardiovaskular
    Suko Adiarto · 2016 · Indonesian Journal of Cardiology
  9. Traitement hypolipidémiant en prévention secondaire
    Jean Ferrières · 2013 · Archives des Maladies du Coeur et des Vaisseaux - Pratique
  10. Acute Coronary Syndromes and Acute Myocardial Infarction
    Steven W. Werns · 2008 · Elsevier eBooks
  11. Lipid-independent Pleiotropic Effects Lipid-independent Pleiotropic Effects of Statins in the Management of Acute of Statins in the Management of Acute Coronary Syndromes Coronary Syndromes
    Kausik Kumar Ray, Christopher Paul Cannon · 2007
  12. What are our chances to reach the new LDL-cholesterol treatment goals in secondary prevention?
    Otto Mayer · 2009 · Cor et Vasa
  13. Rossiyskaya programma LIDER: otsenka izmeneniya kachestva zhizni boL'nykh Ishemicheskoy bolezn'yu serDtsa na fonE teRapii liprimarom
    Karpov IuA, А. Д. Деев · 2006 · Systemic Hypertension
  14. Atorvastatin and standard treatment of Helicobacter pylori : Randomized Clinical Trial
    Mohammad Reza Mohammad Hoseini Azar, Parham Portaghali, Amin Sedokani, Ali Jafari · 2020 · medRxiv
  15. Aplicación sistemática de un algoritmo para el manejo lipídico en pacientes de muy alto riesgo cardiovascular. Impacto en los objetivos lipídicos
    Walter M. Masson, Leonardo Barbagelata, Martín Lee, Daniel Alberto Siniawski, Jose Luis Navarro Estrada, Aníbal Arias, Arturo M. Cagide, Rodolfo Pizarro · 2020 · Revista Argentina de Cardiología
  16. Cardiovascular Risk Factors in Adolescents
    Ayman Khaddam · 2020 · Springer eBooks
  17. A precision medicine approach to lipid monitoring in the secondary prevention of cardiovascular disease
    Rosemary Brown · 2021 · Enlighten: Theses (The University of Glasgow)
  18. Atorvastatin in Helicobacter Pylori Treatment: A Randomized Controlled Trial and Review
    Mohammad Reza Mohammad Hoseini Azar, Parham Porteghali, Amin Sedokani · 2021 · Research Square
  19. Adherence to guideline mandated optimal medical therapy for acute coronary syndrome at Charlotte Maxeke Johannesburg Academic Hospital
    Viwe Mtwesi · 2020
  20. Meta-analysis as a research design – steps demystified for novice medical researchers: a brief review
    Manoj Kumar L · 2021 · Kerala Journal of Psychiatry
  21. The Metabolic Syndrome: 2009
    Charles A. Reasner · 2010 · Humana Press eBooks
  22. Coronary Artery Disease and Cardiomyopathy
    Adam Bierzynski, Dheeraj Khurana, Richard B. Devereux, Varinder Singh · 2017 · Springer eBooks
  23. Coronary Artery Disease and Cardiomyopathy
    Adam Bierzynski, Dheeraj Khurana, Richard B. Devereux, Varinder Singh · 2017 · Springer eBooks
  24. Invited Synopses
    2007 · Acute Cardiac Care
  25. References
    2021 · Wiley eBooks
  26. Management of Dyslipidemia
    Peter Paul Toth · 2018 · Contemporary cardiology
  27. Coronary Artery Disease and Cardiomyopathy
    Adam Bierzynski, Dheeraj Khurana, Varinder Singh · 2016 · Springer eBooks
  28. Lipid management
    Tiziano Angelo Lucchi · 2022 · Wiley eBooks
  29. Cardiovascular Risk Factors in Adolescents
    Ayman Khaddam · 2021 · Springer eBooks
  30. Common hyperlipidaemia
    2007 · CRC Press eBooks
  31. Reply
    Christopher Paul Cannon, Eugene Braunwald M. D · 2007 · Journal of the American College of Cardiology
  32. Comparative Effects Between High-intensity Atorvastatin and Rosuvastatin on New Onset Diabetes Mellitus and Cardiovascular Outcome
    Jah Yeon Choi, Cheol Ung Choi, Byoung Geol Choi, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Jin Oh Na, Jin Won Kim, Eung Ju Kim et al. · 2020
  33. HMG‐CoA‐Reductase Inhibitors
    Mogens Lytken Larsen, Erik Berg Schmidt · 2008 · Springer eBooks
  34. Diabetic dyslipidaemia
    John D. Betteridge · 2011
  35. Which Statin?
    2008 · Obstetrics and Gynecology
  36. Traitement de l'infarctus du myocarde avec sus-décalage du segment ST
    Stéphane Gibaud, X. Dode, Thomas Bochaton, G. Aulagner · 2018 · Elsevier eBooks
  37. Future Directions
    Brian V Reamy · 2008 · Springer eBooks
  38. The ankle–brachial index independently predicted all-cause mortality in high-risk patients with peripheral arterial disease
    Daniel G. Hackam · 2007 · ACP Journal Club
  39. Inflammatory Mechanisms and Treatment of Myocardial Infarction
    Abdelrahman Rizk, Mona F. El-Azab, Reem M. Hazem, Heba M. A. Abdelrazek · 2022 · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences
  40. The Probable Role of Chlamydia pneumoniae Infection in Acute Stroke
    Atakan Yanıkoğlu · 2023 · Infectious diseases
  41. THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I)
    Д. П. Саливончик · 2009 · Health and Ecology Issues
  42. Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
    Alex Bobik, Neale D. Cohen, Alicia Josephine Jenkins, Tin Soe Kyaw, DAVID R. SULLIVAN, Xiaoqian Wu, Xi-Yong Yu, Peter J. Little · 2023 · Contemporary diabetes
  43. Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial
    Junya Ako, Koutaro Yokote, Kenichi Tsujita, Ryohei Tanigawa, Ryo Kamei, Hideki Suganami · 2023 · Journal of Atherosclerosis and Thrombosis
  44. Optimal Target Low-density Lipoprotein Level for Reducing the Risk of Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
    Min-Gyo Jang, Yeung-Eun Son, Hye Duck Choi, Jun‐Woo Kim, Taeeun Kim, Kwang‐Hee Shin · 2023 · Korean Journal of Clinical Pharmacy
  45. Rhabdomyolysis-induced acute kidney injury requiring hemodialysis in a patient on long-term, moderate-intensity rosuvastatin: a case report and literature review
    So‐Young Lee, Suyeon Kim, Jongho Shin, Kyeong Min Kim, Sua Lee · 2024 · Medical Biological Science and Engineering
  46. Fractional Flow Reserve and Angiography Guided Complete Revascularization in Primary Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis
    Kais Hyasat, Edmund Hasche, Hamid Almafragy, Joseph Chiha, Kaleab Asrress, Kevin Liou · 2024 · Angiology
  47. Extensive lipid lowering, thickness of the fibrous caps, and plaque stability
    Shinya Goto, Shinichi Goto · 2024 · European Heart Journal Open
  48. Hyperlipidämie
    Jean‐François Chenot, Aniela Angelow · 2024 · Elsevier eBooks
  49. Screening for Dyslipidemia Among Patients Admitted With Acute Coronary Syndrome at the Jakaya Kikwete Cardiac Institute, Tanzania: A Retrospective Cohort Study
    Nakigunda Kiroga, Zahid Ullah Khan · 2025 · Cureus
  50. Atherogenic index of plasma – a new frontier in predicting peripheral arterial disease risk?
    Anna Lena Hohneck, Oliver Weingaertner · 2025 · VASA
  51. Where is the treatment of atherosclerosis heading?
    Otto Mayer · 2025 · Medicína pro praxi
  52. Statins and Type 1 Diabetes: Impact on Cardiovascular Outcomes and surrogates. Systematic Review and meta-analysis
    Karen Fériz, Pablo Corral, María Bernarda Iriarte-Durán, Claudia Milena Gómez Giraldo, Natalia Nardelli, Oriana Arias‐Valderrama, María Camila Gómez-Ayala · 2025 · Current Diabetes Reports
  53. Acute coronary syndromes, investigations and interventions
    S. Sivapathan, Faraz K. Pathan, Ian Seppelt · 2025 · Elsevier eBooks
  54. Rethinking Statin Dosage in Coronary Disease
    Simon B. Dimmitt, Hans G. Stampfer, Michael Kennedy, Jennifer H. Martin · 2025 · Pharmacology Research & Perspectives
  55. Annexin A1 and annexin A5 in cardiovascular disease
    Dennis H. M. Kusters · 2015
  56. Antecedents, characterisation and validity of cardiovascular disease biomarkers amongst South Asians in the UK
    Julia Chackathayil · 2013 · University of Birmingham Institutional Research Archive (University of Birmingham)
  57. Additional file 1 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
    Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Takeshi Kimura, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Katsumi Miyauchi, Daida, Hiroyuki, Suwa, Satoru et al. · 2022 · Figshare
  58. Additional file 2 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
    Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Takeshi Kimura, Nakagawa, Yoshihisa, Ozaki, Yukio, Hiroshi Iwata, Katsumi Miyauchi, Daida, Hiroyuki, Suwa, Satoru et al. · 2022 · Figshare
  59. Additional file 4 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
    Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Takeshi Kimura, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Katsumi Miyauchi, Daida, Hiroyuki, Suwa, Satoru et al. · 2022 · Figshare
  60. Additional file 1 of Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study
    Kim, Yong Hoon, Her, Ae-Young, Myung Ho Jeong, Kim, Byeong-Keuk, Hong, Sung-Jin, Kim, Seunghwan, Ahn, Chul-Min, Kim, Jung-Sun, 고영국, Choi, Donghoon et al. · 2021 · Figshare
  61. Additional file 3 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
    Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Takeshi Kimura, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Katsumi Miyauchi, Daida, Hiroyuki, Suwa, Satoru et al. · 2022 · Figshare
  62. Additional file 1 of New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins
    Choi, Jah Yeon, Choi, Cheol Ung, Choi, Byoung Geol, Yoonjee Park, Kang, Dong Oh, Won Young Jang, Kim, Woohyeun, Na, Jin Oh, Kim, Jin Won, Kim, Eung Ju et al. · 2021 · Figshare
  63. The efficacy of preoperative evolocumab-rosuvastatin combination therapy in patients with ST-elevation myocardial infarction
    Hongxu Li, Huawei Dong, Shilin Bao, Xuemei Wang, Fu Zuolin · 2026 · PLoS ONE
  64. Development of nanomedicines for inflammation disorders : evaluation of pharmacological efficacy on preclinical models
    Flavio Dormont · 2019 · theses.fr (ABES)
  65. Déterminants métaboliques et génétiques des niveaux de lipoprotéine (a) et du risque cardiovasculaire associé
    Kévin Chemello · 2022 · theses.fr (ABES)
  66. Điều trị rối loạn lipid máu và tỉ lệ đạt cholesterol mục tiêu trên bệnh nhân bị hội chứng mạch vành cấp hoặc bệnh mạch vành ổn định tại Việt Nam - Kết quả từ Nghiên cứu DYSIS II (Dyslipidemia International Study II)
    Nguyen Lan Viet, Pham Nguyen Vinh, Võ Thành Nhân, Do Quang Huan, Phạm Mạnh Hùng, Phan Đình Phong, Đặng Mai Trâm, Baishali Ambegaonka, Carl A Baxte, Philippe Brudi et al. · 2018 · Tạp chí Tim Mạch Học Việt Nam
  67. Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk
    Jun Luo, Yangxin Dai, Chenguang Wu, Chengying Lan, Junwei Shi, Jinfeng Qi, Shimei Hua, Yan An, Lifan Wang, Ping Li et al. · 2026 · Frontiers in Endocrinology
  68. Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis
    Chester B. Good, Steven Do, Samuel K. Peasah · 2026 · JAMA
  69. BindingDB Entry 2451: Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
    BindingDB · 2008 · UC San Diego
  70. Factores de riesgo cardiovascular, control de la dislipemia y uso de hipolipemiantes en el Área Sanitaria II de Asturias
    Miguel Al Kassam Martínez · 2014
  71. Non-statin Therapies for CKD with Dyslipidemia
    István Mucsi · 2014 · Springer eBooks
  72. Synthetic Factor Xa Inhibition in Acute Coronary Syndromes
    Michael Sukhyun Kim, Robert Lee Page II, Ivan P. Casserly · 2009 · Humana Press eBooks